Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

INTRODUCTION: Pembrolizumab was approved in the US as adjuvant treatment of patients with stage IIB or IIC melanoma post-complete resection, based on prolonged recurrence-free survival vs. placebo in the Phase 3 KEYNOTE-716 trial. This study aimed to evaluate the cost-effectiveness of pembrolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shujing, Bensimon, Arielle G., Xu, Ruifeng, Jiang, Ruixuan, Greatsinger, Alexandra, Zhang, Adina, Fukunaga-Kalabis, Mizuho, Krepler, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10271902/
https://www.ncbi.nlm.nih.gov/pubmed/37191852
http://dx.doi.org/10.1007/s12325-023-02525-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10271902/
https://www.ncbi.nlm.nih.gov/pubmed/37191852
http://dx.doi.org/10.1007/s12325-023-02525-x

Ejemplares similares